Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply ...

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, welcomes U.S.

Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial

With approximately $9.5 million in cash reserves and no debt, the Company is ready to leverage strengthened vertical integration as clinical-grade psilocybin moves into Phase IIb trialsNEW YORK, Dec.

Master Market Segmentation for Enhanced Profitability and Growth

Discover how effective market segmentation identifies profitable customers and optimizes pricing, distribution, and product ...
WinBuzzer

OpenAI Deploys GPT-5.2-Codex with ‘Context Compaction’ and Windows Software Optimization

Codex, introducing "context compaction" for long tasks and raising API prices by 40% to target enterprise engineering.